amivantamab

all catalysts(11)

News(9)

• New Taiho, Cullinan data heats up lung cancer drug battle
  The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
  biopharma_dive · 1d ago
• Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
  Taiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.
  biospace · 1d ago
• Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
  Taiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer.…
  endpoints · 1d ago
• Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
  Taiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…
  fiercebiotech · 2d ago
• BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
  Two growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.
  fiercebiotech · 7d ago
• BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
  BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso.
  fiercebiotech · 11d ago
• Summit and Akeso sharpen case for ivonescimab with new Western data
  Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…
  biospace · 23d ago
• BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
  Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperw…
  fiercebiotech · 28d ago
• EGFR-Targeted Therapy Sequencing After Resistance in NSCLC
  Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.
  onclive · 3mo ago